DR1 Antibody

What is DR1 and why is it important in research?

DR1 is a transcriptional repressor that forms a heterodimer with DRAP1 (NC2α) to regulate gene expression. This protein has significant importance in multiple research areas:

• Transcriptional regulation: DR1/DRAP1 heterodimer binds to TBP (TATA-binding protein) and prevents the formation of transcription-competent complexes by inhibiting TFIIA and TFIIB association .

• Disease mechanisms: DR1 activation inhibits vascular smooth muscle cell proliferation through the CSE/H₂S pathway, with implications for diabetic vascular complications .

• Viral pathogenesis: DR1 functions as a host susceptibility factor for influenza A virus replication by suppressing interferon-stimulated gene expression .

• Autoimmunity: HLA-DR1, when incorporated into chimeric antigen receptors, can target pathogenic CD4+ T cells in autoimmune conditions .

The multifunctional nature of DR1 makes antibodies against this protein valuable tools for investigating diverse biological processes.

DR1 protein has a predicted molecular weight of 19 kDa, but may appear at slightly different positions depending on experimental conditions:

• Predicted size: 19 kDa

• Observed size range: 19-26 kDa

The slight variations in observed molecular weight can result from:

• Post-translational modifications

• Sample preparation methods

• Gel concentration and running conditions

• Protein standards used for calibration

When performing Western blot analysis, it is advisable to include positive control lysates like HeLa, 293T, or Jurkat cells, which consistently show strong DR1 expression .

How can DR1 antibodies be used to investigate transcriptional repression mechanisms?

DR1 antibodies are valuable tools for studying its role in transcriptional repression through multiple experimental approaches:

Chromatin Immunoprecipitation (ChIP) Analysis:
ChIP assays using DR1 antibodies have revealed that endogenous DR1 occupies human tRNA genes in HeLa cells . This technique allows researchers to:

• Map DR1 binding sites across the genome

• Determine gene-selective effects of DR1-mediated repression

• Investigate the mechanism by which Dr1 associates with specific promoters

RNAi Combined with DR1 Immunoblotting:
Studies have shown that DR1 knockdown:

• Increases tRNA expression by approximately 2-fold

• Affects specific subsets of RNA polymerase III-transcribed genes

• Has gene-selective effects, with tRNA and Alu genes responding while 5S rRNA, U6 snRNA, and 7SL RNA levels remained unchanged

This methodological approach requires careful quantification of both DR1 protein levels (by Western blotting) and target gene expression (by RT-PCR) following knockdown.

What experimental approaches can be used to study DR1's involvement in disease mechanisms?

DR1 has been implicated in several disease processes, and antibodies can be utilized in various experimental paradigms:

For Vascular Disease Research:
Studies have demonstrated that DR1 activation inhibits vascular smooth muscle cell proliferation through the CSE/H₂S system . Researchers can:

• Use immunoblotting to monitor DR1 expression changes in diabetic versus control tissues

• Combine with proliferation markers (PCNA, Cyclin D1) and pathway regulators (p21)

• Perform co-immunoprecipitation to study DR1 interactions with CSE or CaM

For Viral Infection Studies:
DR1 functions as a host susceptibility factor for influenza A virus replication :

• Western blotting with DR1 antibodies can confirm knockdown efficiency

• Immunoprecipitation can detect associations between DR1 and viral RNA-dependent RNA polymerase (RdRp) components

• Immunofluorescence can visualize subcellular localization changes during infection

For Autoimmune Disease Research:
HLA-DR1 chimeric antigen receptors can target autoimmune T cells :

• Flow cytometry with DR1 antibodies can confirm CAR expression

• Antibodies can help analyze the interaction between DR1-CII CAR T cells and target CD4+ T cells

• Immunohistochemistry can track DR1+ cells in tissues from autoimmune disease models

How do researchers validate DR1 antibody specificity?

Rigorous validation of DR1 antibodies is essential for reliable experimental results. Recommended validation methods include:

• Western blot analysis with positive and negative controls:

  • Use lysates from cells with confirmed DR1 expression (HeLa, 293T, Jurkat)

  • Include lysates from DR1 knockdown cells as negative controls

  • Verify single band at expected molecular weight (~19 kDa)

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide

  • Observe disappearance of specific signal

• Multiple antibody validation:

  • Compare results using antibodies from different sources or raised against different epitopes

  • Confirm similar patterns of detection

• Genetic validation:

  • Use DR1 knockout/knockdown systems

  • Observe loss of signal in Western blot, immunoprecipitation, or immunostaining

• Cross-reactivity assessment:

  • Test antibody in multiple species with conserved DR1 sequence

  • Commercial DR1 antibodies have been validated for human, mouse, and rat samples

What are the optimal conditions for using DR1 antibodies in Western blotting?

Based on published protocols, the following conditions are recommended for optimal DR1 detection by Western blotting:

Sample Preparation:

• Lyse cells using RIPA buffer containing protease inhibitors

• Centrifuge lysates at 12,000g for 30 minutes to remove debris

• Load 10-50 μg of total protein per lane

Electrophoresis and Transfer:

• Use 12-15% SDS-PAGE gels due to DR1's low molecular weight (19 kDa)

• Transfer to PVDF or nitrocellulose membranes at 100V for 1-2 hours

Antibody Incubation:

• Block membranes with 5% non-fat dry milk or BSA in TBST

• Incubate with primary DR1 antibody at 1:1000 dilution overnight at 4°C

• Wash thoroughly with TBST (3 × 10 minutes)

• Incubate with appropriate HRP-conjugated secondary antibody

Detection:

• Develop using ECL technique

• Expected band size: 19-20 kDa

How should co-immunoprecipitation experiments be designed when studying DR1 protein interactions?

Co-immunoprecipitation is an effective technique for studying DR1 interactions with binding partners such as DRAP1, CSE, or CaM:

Protocol Parameters:

• Cell preparation:

  • Seed equal number of cells (2.0×10⁵ per plate) in 60 mm² plates

  • Apply appropriate treatments to modulate DR1 interactions

• Lysis conditions:

  • Lyse cells in RIPA buffer with 10% protease inhibitor for 30 minutes

  • Centrifuge at 12,000g for 30 minutes to clear lysates

• Immunoprecipitation:

  • Incubate with 2 μg DR1 antibody overnight at 4°C

  • Couple to Protein A/G Magnetic Beads for 2 hours

  • Wash extensively to remove non-specific interactions

• Controls:

  • Include IgG isotype control

  • Include lysate without antibody as negative control

  • Perform reverse immunoprecipitation with antibody against suspected binding partner

Results Interpretation:

• The yeast and human Dr1/DRAP1 interaction is species-specific, with human Dr1 interacting only with human DRAP1, not yeast Bur6

• Verification of interactions should be performed by both forward and reverse co-immunoprecipitation

What are the critical considerations for studying DR1 in the context of gene expression regulation?

When investigating DR1's role in transcriptional regulation, researchers should consider:

Experimental Design:

• Gene-specific effects: DR1 repression shows gene selectivity, affecting tRNA and Alu genes but not 5S rRNA, U6 snRNA, or 7SL RNA expression

• RNAi approach:

  • Use multiple siRNAs targeting different regions of DR1 to exclude off-target effects

  • A 40-60% reduction in DR1 protein levels is sufficient to observe phenotypic effects

  • Monitor both mature transcripts and short-lived primary transcripts (pre-tRNAs) to assess ongoing transcription accurately

• Normalization controls:

  • Multiple reference genes (ARPP P0, GAPDH, TFIIB) should be tested for normalization

  • Include assay saturation controls to ensure changes in transcript levels give clear changes in signal intensity

• Overexpression studies:

  • DR1 overexpression decreases mRNA accumulation and impairs cell growth

  • Effects can be rescued by TBP overexpression, confirming DR1's mechanism of action

  • DR1 overexpression affects RNA polymerase III transcripts but not RNA polymerase I transcripts

How can DR1 antibodies be employed in studying disease mechanisms like influenza viral infection?

DR1 antibodies are valuable tools for investigating the role of DR1 in influenza A virus (IAV) replication:

Experimental Approaches:

• DR1 knockdown validation:

  • Use DR1 antibodies to confirm protein reduction after siRNA treatment

  • A genome-wide RNAi screen identified DR1 as a positive host factor in IAV replication

• Protein-protein interaction studies:

  • DR1 associates with all three subunits of the viral RNA-dependent RNA polymerase (RdRp) complex

  • Co-immunoprecipitation with DR1 antibodies can pull down viral RdRp components

• Pathway analysis:

  • Prolonged DR1 knockdown induces interferon-stimulated gene expression

  • DR1 normally suppresses IFN induction, creating conditions favorable for IAV replication

  • DR1 antibodies can help monitor this suppression mechanism

• Biochemical assays:

  • DR1 enhances viral RNA replication

  • Antibodies can be used to deplete DR1 from extracts in in vitro replication assays

This multi-faceted approach reveals that DR1 represents a host susceptibility gene for IAV replication through two mechanisms: suppressing host defense and directly enhancing viral RNA replication.

What are common problems encountered when using DR1 antibodies and how can they be resolved?

How should researchers interpret variation in DR1 detection across different experimental systems?

Variations in DR1 detection can result from biological differences or technical factors:

Biological Variations:

• Expression levels: DR1 expression is decreased in diabetic mice compared to controls

• Protein interactions: DR1 forms species-specific complexes with DRAP1/Bur6

• Disease states: DR1 activation is reduced in vascular tissues from diabetic models

Technical Considerations:

• Antibody specificity: Different epitopes may be differentially accessible in certain experimental contexts

• Sample preparation: The protocol used for tissue/cell lysis can affect DR1 detection

• Fixation methods: For immunohistochemistry, fixation conditions can impact epitope accessibility

When encountering unexpected variations, researchers should:

• Validate findings with multiple antibodies

• Compare results across different techniques (WB, IP, IHC)

• Include appropriate positive and negative controls

• Consider the biological context of the experimental system

What emerging applications of DR1 antibodies show promise for disease research?

Recent studies suggest several promising directions for DR1 antibody use in disease research:

Vascular Disease and Diabetes:
DR1 activation inhibits vascular smooth muscle cell proliferation via the CSE/H₂S system by increasing Ca²⁺-CaM binding, which inhibits the IGF-1/IGF-1R and HB-EGF/EGFR pathways . This suggests potential therapeutic targets for diabetic vascular complications that could be studied using DR1 antibodies.

Autoimmune Disease Therapy:
The development of HLA-DR1 chimeric antigen receptors that target CD4+ T cells in an antigen-specific manner represents a novel approach to autoimmune disease treatment . DR1 antibodies will be essential for:

• Confirming CAR construct expression

• Monitoring target cell populations

• Assessing treatment efficacy in preclinical models

Viral Infection Mechanisms:
DR1's role as a host susceptibility factor for influenza virus replication through dual mechanisms (suppressing host defense and enhancing viral RNA replication) identifies it as a potential therapeutic target . DR1 antibodies will be valuable for:

• High-throughput screening of compounds that modulate DR1 activity

• Investigating DR1's role in other viral infections

• Developing host-directed antiviral strategies

How can new antibody technologies enhance DR1 research?

Emerging antibody technologies offer new opportunities for DR1 research:

Single-cell Antibody Methods:

• Single-cell Western blotting can reveal cell-to-cell variations in DR1 expression

• Mass cytometry with DR1 antibodies can quantify DR1 levels across heterogeneous cell populations

Proximity Labeling Techniques:

• BioID or APEX2 fusions with DR1 can identify proximal proteins in living cells

• These approaches could reveal novel DR1 interaction partners beyond known associates like DRAP1

Intrabodies and Nanobodies:

• Development of DR1-specific intrabodies could enable real-time visualization of DR1 dynamics

• Single-domain antibodies (nanobodies) against DR1 could provide higher resolution for structural studies

Antibody-drug Conjugates:

• For therapeutic applications targeting DR1-expressing cells in disease contexts

• Could be particularly relevant for the autoimmune applications described with DR1-CAR technology